Regulators approved the injection, which significantly cuts administration time versus the intravenous formulation, based on a Phase III comparison of the two.

The firms will use the funds to integrate FYR's liquid biopsy platform in NuvOx's Phase II trial evaluating the oxygen therapeutic NanO₂ as a radiosensitizer.

The Shanghai-based firm will evaluate the safety of the therapy and its efficacy in reducing urinary oxalate levels and improving renal outcomes.

The agency considered clinical trial data showing Redemplo can significantly reduce triglyceride levels in patients with familial chylomicronemia syndrome versus placebo.

NEW YORK – Radiopharm Theranostics on Tuesday said it was cleared by Australian regulators to begin a Phase I trial of its KLK3-targeting radiotherapeutic, RAD 402, for the treatment of metastatic or ...

CureMatch will analyze molecular profiles of US Special Operations Forces cancer patients and produce reports with treatment strategies.

The gene therapy will utilize the firm's suprachoroidal vector coAAV-SCS, which it says will be an effective and less burdensome treatment alternative.

They face a difficult choice, since the treatment may benefit their children but comes with serious risks and unknowns, particularly following reports of patient deaths.

The recommendation is based on the Phase II/III DEVOTE study testing the higher dose in treatment-naïve patients and those already on the low dose.

The company plans to use the proceeds to test its TCR-T cell therapy in patients with MAGE-A4-positive solid tumors.

A sponsor will have to demonstrate success with "with several consecutive patients with different bespoke therapies" to ...

Investigators at Boston institutions believe the regimen could target immunosuppressive lipid macrophages and improve ...